Sugi Predict

Sugi Predict / Targets / SLC22A2

SLC22A2

Solute carrier family 22 member 2 · O15244 · SLC22A2 on Sugi Atlas →

64,098 patent compounds predicted against SLC22A2, 48,673 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL80356 SCHEMBL80356 0.74 20/20
SCHEMBL82784 SCHEMBL82784 0.74 20/20
SCHEMBL79992 SCHEMBL79992 0.73 20/20
SCHEMBL81428 SCHEMBL81428 0.67 20/20
SCHEMBL81213 SCHEMBL81213 0.66 20/20
SCHEMBL80583 SCHEMBL80583 0.64 20/20
SCHEMBL82856 SCHEMBL82856 0.62 20/20
SCHEMBL85979 SCHEMBL85979 0.75 19/20
SCHEMBL85981 SCHEMBL85981 0.75 19/20
SCHEMBL82049 SCHEMBL82049 0.75 19/20
SCHEMBL82085 SCHEMBL82085 0.72 19/20
SCHEMBL86225 SCHEMBL86225 0.71 19/20
SCHEMBL81807 SCHEMBL81807 0.71 19/20
SCHEMBL81290 SCHEMBL81290 0.71 19/20
SCHEMBL80975 SCHEMBL80975 0.70 19/20
SCHEMBL81333 SCHEMBL81333 0.69 19/20
SCHEMBL82515 SCHEMBL82515 0.69 19/20
SCHEMBL80723 SCHEMBL80723 0.69 19/20
SCHEMBL82516 SCHEMBL82516 0.69 19/20
Dolutegravir Dolutegravir (SCHEMBL80619) 1.00 18/20

Clinical trials — most relevant to SLC22A2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Genetic Basis for Variation in the Renal Elimination of Metformin PHASE4COMPLETED
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use PHASE4COMPLETED
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation PHASE2/PHASE3UNKNOWN
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery PHASE2COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Cancer and Hearing Loss Related in Children nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient nanUNKNOWN
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia nanCOMPLETED
Autonomic Function in Patients With COPD nanCOMPLETED
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Genetics of Hyperuricemia Therapy in Hmong nanCOMPLETED
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Effect of Pharmacogenetics on Imatinib Plasma Level and Response nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL nanCOMPLETED
Coproporphyrine Isomers and Methotrexate Elimination nanCOMPLETED
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders nanUNKNOWN
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
Gyrate Atrophy Ocular and Systemic Study nanACTIVE_NOT_RECRUITING
Harmonic Ratio in Patients With GLUT1 Deficiency Syndrome nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC22A2 binder may also engage these)

ProteinNameSimilarity
Q9R0W2 — 1.000 Q9R0W2 →
Q5R5H7 — 1.000 Q5R5H7 →
O02713 — 0.999 O02713 →
Q8MJI6 — 0.998 Q8MJI6 →
O70577 — 0.995 O70577 →
O08966 — 0.993 O08966 →
O76082 — 0.993 O76082 →
O77504 — 0.992 O77504 →
Q9Z0E8 — 0.990 Q9Z0E8 →
O88446 — 0.990 O88446 →
Q9R141 — 0.990 Q9R141 →
SLC22A3 Solute carrier family 22 member 3 0.989 landscape →
A9CB25 — 0.989 A9CB25 →
Q63089 — 0.989 Q63089 →
SLC22A1 Solute carrier family 22 member 1 0.989 landscape →
SLC22A4 Solute carrier family 22 member 4 0.989 landscape →
O70594 — 0.988 O70594 →
Q9Z306 — 0.987 Q9Z306 →
Q863T6 — 0.987 Q863T6 →
Q9WTN6 — 0.986 Q9WTN6 →
Q9WTW5 — 0.985 Q9WTW5 →
A7MBE0 — 0.984 A7MBE0 →
Q961J5 — 0.980 Q961J5 →
O57379 — 0.980 O57379 →
Q66J54 — 0.977 Q66J54 →
B2GV36 — 0.977 B2GV36 →
Q91WU2 — 0.976 Q91WU2 →
Q28ES4 — 0.976 Q28ES4 →
Q9R1U7 — 0.975 Q9R1U7 →
Q9VCA2 — 0.975 Q9VCA2 →